Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Mellitus of Different Ethnicity

卡格列净 医学 队列 安慰剂 内科学 耐受性 体质指数 2型糖尿病 2型糖尿病 队列研究 不利影响 糖尿病 内分泌学 病理 替代医学
作者
Jaime A. Davidson,Richard Auilar,Fernando Javier Lavalle González,Angelina Trujillo,Maria Alba,Ujjwala Vijapurkar,Gary Meininger
出处
期刊:Ethnicity & Disease [Ethnicity & Disease, Inc.]
卷期号:26 (2): 221-221 被引量:9
标识
DOI:10.18865/ed.26.2.221
摘要

<p><strong>Objective</strong>: To assess the efficacy and safety of the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin in patients of different ethnicities.</p><p><strong>Design, Setting, and Patients:</strong> Post hoc analysis of data pooled from four randomized, placebo-controlled, phase 3 studies of adults with inadequately controlled type 2 diabetes mellitus (T2DM).</p><p><strong>Interventions:</strong> Once daily oral canagliflozin 100 mg or 300 mg, or placebo.</p><p><strong>Main Outcome Measures:</strong> Efficacy endpoints included change from baseline in HbA1c, body weight (BW), systolic blood pressure (SBP), and lipids at week 26; safety and tolerability were assessed by adverse event reports.</p><p><strong>Results:</strong> Of the 2,313 patients included in this pooled analysis, 609 self-identified as Hispanic/Latino. Hispanic/Latino patients had a mean age of 54 years, mean duration of T2DM of 7 years, mean HbA1c of 8.1%, mean body mass index of 31.2 kg/m2, and mean SBP of 126.1 mm Hg. There were more women in the non-Hispanic/Latino cohort (63%) compared with the Hispanic/ Latino cohort. Placebo-subtracted changes in HbA1c were −.82% with canagliflozin 100 mg and −.94% with canagliflozin 300 mg in the Hispanic/Latino cohort, which were similar to reductions observed in the non-Hispanic/Latino cohort. Significantly greater dose-related reductions in HbA1c, BW, and SBP were observed with both canagliflozin doses compared with placebo. Canagliflozin was generally well-tolerated. Genital mycotic infections were less frequent in Hispanic/Latino women than in non-Hispanic/Latino women.</p><p><strong>Conclusions:</strong> The SGLT2 inhibitor canagliflozin was generally well-tolerated and was associated with clinically meaningful reductions in HbA1c, BW, and SBP in both Hispanic/Latino and non-Hispanic/ Latino patients with T2DM. <em>Ethn Dis.</em> 2016;26(1):221-228; doi:10.18865/ ed.26.2.221</p>
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星星发布了新的文献求助10
1秒前
科研通AI2S应助极速小鱼采纳,获得10
1秒前
萌&发布了新的文献求助10
2秒前
3秒前
4秒前
4秒前
821108pan发布了新的文献求助10
6秒前
充电宝应助youyou采纳,获得10
6秒前
慢半拍完成签到,获得积分10
6秒前
李健的小迷弟应助HopeStar采纳,获得10
6秒前
6秒前
7秒前
萌&完成签到,获得积分10
8秒前
慢半拍发布了新的文献求助10
8秒前
哭泣灯泡完成签到,获得积分10
9秒前
Ava应助药石无医采纳,获得10
9秒前
楚狂人发布了新的文献求助10
9秒前
李靖完成签到 ,获得积分10
10秒前
无奈的惜蕊完成签到,获得积分10
12秒前
zhujiji发布了新的文献求助10
12秒前
骏驰天下完成签到,获得积分10
14秒前
14秒前
平常化蛹发布了新的文献求助10
15秒前
honphyjiang完成签到,获得积分10
15秒前
16秒前
大曼曼曼曼完成签到,获得积分10
16秒前
18秒前
国足预备员完成签到 ,获得积分10
18秒前
HopeStar发布了新的文献求助10
18秒前
kelvin发布了新的文献求助10
19秒前
自然的霸完成签到,获得积分10
20秒前
daniel完成签到,获得积分10
22秒前
23秒前
hjh发布了新的文献求助10
23秒前
秋风暖暖完成签到,获得积分0
24秒前
24秒前
龙共完成签到,获得积分10
24秒前
26秒前
年轻元冬完成签到,获得积分10
27秒前
药石无医发布了新的文献求助10
28秒前
高分求助中
(应助此贴封号)【重要!!请各位详细阅读】【科研通的精品贴汇总】 10000
F-35B V2.0 How to build Kitty Hawk's F-35B Version 2.0 Model 2000
中国兽药产业发展报告 1000
Biodegradable Embolic Microspheres Market Insights 888
Quantum reference frames : from quantum information to spacetime 888
The Netter Collection of Medical Illustrations: Digestive System, Volume 9, Part III - Liver, Biliary Tract, and Pancreas (3rd Edition) 600
Pediatric Injectable Drugs 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4450392
求助须知:如何正确求助?哪些是违规求助? 3918315
关于积分的说明 12161985
捐赠科研通 3568216
什么是DOI,文献DOI怎么找? 1959430
邀请新用户注册赠送积分活动 998797
科研通“疑难数据库(出版商)”最低求助积分说明 893880